Il Yang Pharmaceutical's Noltec Plus is maintaining its growth trajectory and expanding its presence in the next-generation gastrointestinal disease treatment market.
The company announced on July 9 that the outpatient prescription amount for Noltec Plus reached 2.4 billion won in the second quarter of this year, marking a 13.7% increase from the first quarter.
According to the pharmaceutical market research firm UBIST, the monthly prescription amount for Noltec Plus rose from approximately 300 million won in June of last year to 860 million won during the same period this year, representing an increase of over 205% year-on-year.
The 'Noltec (Noltec + Noltec Plus) product line' also saw its monthly prescription amount reach 4.5 billion won in June, a 15.6% increase compared to the same month last year, indicating that the synergy within the Noltec product line is becoming more pronounced.
Noltec Plus is a combination drug that combines the domestic new drug Noltec (ilaprazole) with the antacid sodium bicarbonate, which has received approval for short-term treatment of erosive esophagitis. This is the first combination drug introduced in about 16 years since the launch of Noltec, characterized by maintaining existing therapeutic effects while enhancing the speed of action.
According to the company, Noltec Plus is designed to temporarily adjust the acidity in the stomach with the antacid to facilitate the rapid absorption of ilaprazole. It allows for quick onset of action and can be used in the treatment of erosive esophagitis accompanied by mucosal damage.
Notably, Noltec Plus demonstrated the best results in the key pharmacodynamic evaluation parameter of integrated gastric acid reduction among proton pump inhibitor (PPI) combination drugs. The time to reach maximum blood concentration also showed comparable or superior indicators compared to potassium-competitive acid blockers (P-CAB) and existing PPI combination drugs, proving its excellent pharmacodynamic profile.
An Il Yang Pharmaceutical official stated, "We will expand our engagement with healthcare professionals through symposiums and academic marketing activities, and we aim to enhance our competitiveness in the gastrointestinal disease treatment market based on robust data from Noltec and Noltec Plus."
Meanwhile, the company is accelerating the normalization of its local business by resuming exports of its flagship ginseng drink, Wonbidi, to China.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.